SAN ANTONIO (EGMN) - Zoledronic acid proved dramatically effective in preventing the pronounced bone loss that accompanies combination estrogen-reducing adjuvant endocrine therapy in premenopausal breast cancer patients, according to an update from a major Austrian clinical trial.Indeed, the number of such patients who needed to be treated (NNT) with the third-generation bisphosphonate to prevent one additional case of osteopenia at 3 years was just 4.5 in the Austrian Breast and Colorectal Cancer...